133 related articles for article (PubMed ID: 15197355)
21. Development of Inhibitors Targeting Hypoxia-Inducible Factor 1 and 2 for Cancer Therapy.
Yu T; Tang B; Sun X
Yonsei Med J; 2017 May; 58(3):489-496. PubMed ID: 28332352
[TBL] [Abstract][Full Text] [Related]
22. YC-1: a potential anticancer drug targeting hypoxia-inducible factor 1.
Yeo EJ; Chun YS; Cho YS; Kim J; Lee JC; Kim MS; Park JW
J Natl Cancer Inst; 2003 Apr; 95(7):516-25. PubMed ID: 12671019
[TBL] [Abstract][Full Text] [Related]
23. Hypoxia-inducible factor-1 alpha as a therapeutic target for primary effusion lymphoma.
Shrestha P; Davis DA; Veeranna RP; Carey RF; Viollet C; Yarchoan R
PLoS Pathog; 2017 Sep; 13(9):e1006628. PubMed ID: 28922425
[TBL] [Abstract][Full Text] [Related]
24. Hypoxia-inducible factor (HIF) inhibitors: a patent survey (2011-2015).
Ban HS; Uto Y; Won M; Nakamura H
Expert Opin Ther Pat; 2016; 26(3):309-22. PubMed ID: 26882240
[TBL] [Abstract][Full Text] [Related]
25. Role of hypoxia-inducible factor-1alpha as a cancer therapy target.
Patiar S; Harris AL
Endocr Relat Cancer; 2006 Dec; 13 Suppl 1():S61-75. PubMed ID: 17259560
[TBL] [Abstract][Full Text] [Related]
26. Hypoxia-inducible factor-1 (HIF-1) inhibitors from the last decade (2007 to 2016): A "structure-activity relationship" perspective.
Bhattarai D; Xu X; Lee K
Med Res Rev; 2018 Jul; 38(4):1404-1442. PubMed ID: 29278273
[TBL] [Abstract][Full Text] [Related]
27. New anticancer strategies targeting HIF-1.
Yeo EJ; Chun YS; Park JW
Biochem Pharmacol; 2004 Sep; 68(6):1061-9. PubMed ID: 15313402
[TBL] [Abstract][Full Text] [Related]
28. Exploitation of the HIF axis for cancer therapy.
Escuin D; Simons JW; Giannakakou P
Cancer Biol Ther; 2004 Jul; 3(7):608-11. PubMed ID: 15197342
[TBL] [Abstract][Full Text] [Related]
29. Proresolution effects of hydrogen sulfide during colitis are mediated through hypoxia-inducible factor-1α.
Flannigan KL; Agbor TA; Motta JP; Ferraz JG; Wang R; Buret AG; Wallace JL
FASEB J; 2015 Apr; 29(4):1591-602. PubMed ID: 25550470
[TBL] [Abstract][Full Text] [Related]
30. Recent advances in hypoxia-inducible factor (HIF)-1 inhibitors.
Xia Y; Choi HK; Lee K
Eur J Med Chem; 2012 Mar; 49():24-40. PubMed ID: 22305612
[TBL] [Abstract][Full Text] [Related]
31. Identification of small molecule inhibitors of hypoxia-inducible factor 1 transcriptional activation pathway.
Rapisarda A; Uranchimeg B; Scudiero DA; Selby M; Sausville EA; Shoemaker RH; Melillo G
Cancer Res; 2002 Aug; 62(15):4316-24. PubMed ID: 12154035
[TBL] [Abstract][Full Text] [Related]
32. HIF-1 and tumor progression: pathophysiology and therapeutics.
Semenza GL
Trends Mol Med; 2002; 8(4 Suppl):S62-7. PubMed ID: 11927290
[TBL] [Abstract][Full Text] [Related]
33. Current insights and future perspectives of hypoxia-inducible factor-targeted therapy in cancer.
Ajith TA
J Basic Clin Physiol Pharmacol; 2018 Dec; 30(1):11-18. PubMed ID: 30260792
[TBL] [Abstract][Full Text] [Related]
34. Inhibiting hypoxia-inducible factor 1 for cancer therapy.
Melillo G
Mol Cancer Res; 2006 Sep; 4(9):601-5. PubMed ID: 16940159
[TBL] [Abstract][Full Text] [Related]
35. Advances in inhibition of protein-protein interactions targeting hypoxia-inducible factor-1 for cancer therapy.
Li J; Xi W; Li X; Sun H; Li Y
Bioorg Med Chem; 2019 Apr; 27(7):1145-1158. PubMed ID: 30819620
[TBL] [Abstract][Full Text] [Related]
36. Chemical biology approach for the development of hypoxia inducible factor (HIF) inhibitor LW6 as a potential anticancer agent.
Naik R; Han S; Lee K
Arch Pharm Res; 2015 Sep; 38(9):1563-74. PubMed ID: 26310207
[TBL] [Abstract][Full Text] [Related]
37. Hypoxia-inducible factor: Achilles' heel of antiangiogenic cancer therapy (review).
Blagosklonny MV
Int J Oncol; 2001 Aug; 19(2):257-62. PubMed ID: 11445836
[TBL] [Abstract][Full Text] [Related]
38. Evaluating hypoxia-inducible factor-1alpha as a cancer therapeutic target via inducible RNA interference in vivo.
Li L; Lin X; Staver M; Shoemaker A; Semizarov D; Fesik SW; Shen Y
Cancer Res; 2005 Aug; 65(16):7249-58. PubMed ID: 16103076
[TBL] [Abstract][Full Text] [Related]
39. Anticancer imidazoacridinone C-1311 inhibits hypoxia-inducible factor-1α (HIF-1α), vascular endothelial growth factor (VEGF) and angiogenesis.
Paradziej-Łukowicz J; Skwarska A; Peszyńska-Sularz G; Brillowska-Dąbrowska A; Konopa J
Cancer Biol Ther; 2011 Oct; 12(7):586-97. PubMed ID: 21775820
[TBL] [Abstract][Full Text] [Related]
40. Cell type-specific, topoisomerase II-dependent inhibition of hypoxia-inducible factor-1alpha protein accumulation by NSC 644221.
Creighton-Gutteridge M; Cardellina JH; Stephen AG; Rapisarda A; Uranchimeg B; Hite K; Denny WA; Shoemaker RH; Melillo G
Clin Cancer Res; 2007 Feb; 13(3):1010-8. PubMed ID: 17289897
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
